Stock 1AI ALGORAE PHARMACEUTICALS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Algorae Pharmaceuticals Limited Share Price

Equities

1AI

AU0000296022

Biotechnology & Medical Research

Market Closed - Australian S.E.
Other stock markets
 07:10:44 26/04/2024 BST 		5-day change 1st Jan Change
0.01 AUD 0.00% Intraday chart for Algorae Pharmaceuticals Limited -9.09% 0.00%
03-08 Algorae Pharmaceuticals Nears Launch of Drug Discovery Platform MT
02-28 Algorae Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI

Financials

Sales 2022 3.4K 2.22K 178K Sales 2023 42.02K 27.44K 2.2M Capitalization 23.4M 15.29M 1.22B
Net income 2022 -1M -653K -52.29M Net income 2023 -2M -1.31M -105M EV / Sales 2022 1,775 x
Net cash position 2022 4.24M 2.77M 222M Net cash position 2023 4.11M 2.69M 215M EV / Sales 2023 459 x
P/E ratio 2022
-3.58 x
P/E ratio 2023
-9.38 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 59.39%
More Fundamentals * Assessed data

Chart Algorae Pharmaceuticals Limited

Dynamic Chart

Latest news about Algorae Pharmaceuticals Limited

Algorae Pharmaceuticals Nears Launch of Drug Discovery Platform MT
Algorae Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
Algorae Pharmaceuticals Considers Combination Therapy for NTCELL Trial MT
Algorae Pharmaceuticals Limited Announces Change of Company Secretary CI
Algorae Pharmaceuticals, HL Pharma Partner to Develop Cannabinoid Compound Storage and AI Platform MT
Algorae Pharmaceuticals Secures Agreement with HL Pharma MT
Algorae, Monash University Collaborate on Pre-Clinical Studies for Cardiovascular Diseases Drug; Shares Plunge 8% MT
Algorae Joins CSIRO's Next Generation AI Graduate Program with Grant Funding Participation; Shares Jump 8% MT
Algorae Pharmaceuticals Enters Partnership for Developing Drug Discovery AI Platform MT
Algorae Pharmaceuticals Limited announced that it has received AUD 0.001125 million in funding CI
Living Cell Technologies Collaborating With La Trobe University for Dementia Drug Candidate MT
Living Cell Technologies Limited has Changed its Name to Algorae Pharmaceuticals Limited CI
Living Cell Technologies Limited Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Living Cell Technologies Files Provisional Patent Application for CBD-Combination Drug Candidate for Dementia MT
Living Cell Technologies May Change Name to Algorae Pharmaceuticals; Shares Rise 6% MT
More news

Press releases Algorae Pharmaceuticals Limited

Living Cell Technologies : June Quarter 2022 PU
Living Cell Technologies : Quarterly Activity Report and Appendix 4C PU
Living Cell Technologies : Change of Director's Interest Notice - B Tuch and A Kelly PU
Living Cell Technologies : Investor Presentation - Gold Coast Investment Showcase PU
Living Cell Technologies : Application for quotation of securities - LCT PU
More press releases

Quotes and Performance

1 week-9.09%
1 month+11.11%
3 months+11.11%
6 months-9.09%
More quotes

Highs and lows

1 week
0.01
Extreme 0.009
0.01
1 month
0.01
Extreme 0.009
0.01
Current year
0.01
Extreme 0.009
0.01
1 year
0.01
Extreme 0.008
0.02
3 years
0.00
Extreme 0.004
0.02
5 years
0.00
Extreme 0.004
0.06
10 years
0.00
Extreme 0.004
0.28
More quotes

Managers and Directors - Algorae Pharmaceuticals Limited

Managers TitleAgeSince
Daya Uka DFI
 Director of Finance/CFO - 31/12/15
James Mckenna CTO
 Chief Tech/Sci/R&D Officer - 18/06/23
Belinda di Bartolo COO
 Chief Operating Officer - 12/12/21
Members of the board TitleAgeSince
David Hainsworth CHM
 Chairman 50 30/10/22
Bradley Dilkes BRD
 Director/Board Member 39 30/10/22
Bradley Latham BRD
 Director/Board Member 62 02/07/23
More insiders

Quotes

Date Price Change Volume
26/04/24 0.01 0.00% 1,835,709
24/04/24 0.01 0.00% 1,581,361
23/04/24 0.01 0.00% 1,294,618
22/04/24 0.01 -9.09% 2,268,829
19/04/24 0.011 0.00% 4,427,760

Delayed Quote Australian S.E., April 26, 2024 at 07:10 am

More quotes

Company Profile

Algorae Pharmaceuticals Limited, formerly Living Cell Technologies Limited, is an Australia-based pharmaceutical development company. The Company is focused on discovering and developing novel treatments for medical conditions with under met medical needs. Its programs include AlgoraeOS, Dementia and Parkinson’s. Its drug candidates include NTCELL for Parkinson’s disease and the AI-116 combination drug candidate for dementia. AlgoraeOS is a closed-loop platform, leveraging advanced computational tools to generate novel insights in-silico that are being developed to initiate or accelerate therapeutic programs. The AI-116 is a novel combination drug candidate made up of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. The NTCELL is an alginate coated capsule product containing clusters of neonatal porcine choroid plexus cells that are injected into the damaged site within the brain to target the treatment of Parkinson’s disease.
Sector
Biotechnology & Medical Research
Calendar
27/08/2024 - Q4 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ALGORAE PHARMACEUTICALS LIMITED Stock Algorae Pharmaceuticals Limited
0.00% 11M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 1AI Stock